The FDA is now allowing 23andMe to sell genetic tests again. I don’t believe the test looks for any alpha-synuclein, MAPT, or other tau-related genetic mutations so any genetic test from 23andMe won’t have any bearing on the disorders with the Brain Support Network community. However, this is still big news for the genetic testing world. According to the article, customers have to specifically ask to be tested for Alzheimer’s and Parkinson’s risk.
Here’s a link to today’s New York Times article on the development:
www.nytimes.com/2017/04/06/health/fda-genetic-tests-23andme.html Health
F.D.A. Will Allow 23andMe to Sell Genetic Tests for Disease Risk to Consumers
By Gina Kolata
New York Times
April 6, 2017Robin
F.D.A. Will Allow 23andMe to Sell Genetic Tests for Disease Risk to Consumers
By Gina Kolata
New York Times
April 6, 2017Robin